Add-on Acquisition • Life Science

Algernon Pharmaceuticals Acquires NIC

On May 13, 2025, Algernon Pharmaceuticals acquired life science company NIC

Acquisition Context

This is Algernon Pharmaceuticals’ 1st transaction in the Life Science sector.
This is Algernon Pharmaceuticals’ 1st transaction in the United States.

Explore All 3111 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	May 13, 2025
Target	NIC
Sector	Life Science
Buyer(s)	Algernon Pharmaceuticals
Deal Type	Add-on Acquisition

Target Company

NIC

United States

NIC is a clinical stage drug development company.

Explore More Deals

Browse All 215,262 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Algernon Pharmaceuticals

Vancouver, British Columbia, Canada

Category	Company
Sector	Life Science

DESCRIPTION

Algernon Pharmaceuticals is a healthcare and clinical stage pharmaceutical development company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals is headquartered in Vancouver, British Columbia.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
Country: United States	1 of 1
Year: 2025	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - United States M&A - 2025 M&A